Technology
Platforms
Science
Partners
Team
Contact
Get in touch
Get in touch

Enabling Regenerative Biologics

Advancing the future of regenerative science.

Advancing the future of

regenerative science.

Our Technology
Platform Overview

The Celligenics Secretome Platform

As people live longer, the challenge is no longer only to extend life, but to improve the quality of living. Ageing, injury and chronic conditions can slow the body’s natural ability to repair and recover.

Stem cells are known for their regenerative potential, but much of their benefit comes from the regenerative substances they release. These include growth factors, cytokines, peptides and extracellular vesicles, collectively known as the secretome.

Celligenics harnesses the stem cell secretome to translate regenerative science into real-world applications. Our advantage begins with source-led purity, supported by the broader benefits of a cell-free and complete secretome platform.

Source-Led Purity

Selected stem cell sources and proprietary source-to-secretome know-how support a purer, more consistent profile, translating into stronger regenerative performance.

Source-Led Purity

Selected stem cell sources and proprietary source-to-secretome know-how support a purer, more consistent profile, translating into stronger regenerative performance.

Source-Led Purity

Selected stem cell sources and proprietary source-to-secretome know-how support a purer, more consistent profile, translating into stronger regenerative performance.

Cell-Free Regeneration

Captures the benefits of stem cell science without live-cell delivery, reducing complexity around safety, ethics and regulation.

Cell-Free Regeneration

Captures the benefits of stem cell science without live-cell delivery, reducing complexity around safety, ethics and regulation.

Cell-Free Regeneration

Captures the benefits of stem cell science without live-cell delivery, reducing complexity around safety, ethics and regulation.

Complete Secretome

A broader regenerative profile beyond exosome-only approaches, combining multiple cell-released components that work together to support repair and recovery.

Complete Secretome

A broader regenerative profile beyond exosome-only approaches, combining multiple cell-released components that work together to support repair and recovery.

Complete Secretome

A broader regenerative profile beyond exosome-only approaches, combining multiple cell-released components that work together to support repair and recovery.

our technology in action

Celligenics At A Glance

Application Verticals

One Technology.
Multiple Applications.

Built from a single secretome technology base, Celligenics’ platform is designed to extend across multiple regenerative fields, from near-term commercial applications to longer-term clinical and biological opportunities.

Therapeutics

Developed for tissue repair, functional recovery and degenerative conditions where regenerative biologics may support unmet clinical needs.

Therapeutics

Developed for tissue repair, functional recovery and degenerative conditions where regenerative biologics may support unmet clinical needs.

Therapeutics

Developed for tissue repair, functional recovery and degenerative conditions where regenerative biologics may support unmet clinical needs.

Cosmeceuticals

Formulated for advanced skin renewal, post-procedure recovery and aesthetic care, from professional clinic use to daily care.

Cosmeceuticals

Formulated for advanced skin renewal, post-procedure recovery and aesthetic care, from professional clinic use to daily care.

Cosmeceuticals

Formulated for advanced skin renewal, post-procedure recovery and aesthetic care, from professional clinic use to daily care.

Veterinary

Applied to animal health needs such as wound recovery, mobility support and tissue repair, with potential across companion and performance animals.

Veterinary

Applied to animal health needs such as wound recovery, mobility support and tissue repair, with potential across companion and performance animals.

Veterinary

Applied to animal health needs such as wound recovery, mobility support and tissue repair, with potential across companion and performance animals.

Longevity

Centred on wellness-oriented solutions for healthy ageing, recovery, resilience and long-term biological function.

Longevity

Centred on wellness-oriented solutions for healthy ageing, recovery, resilience and long-term biological function.

Longevity

Centred on wellness-oriented solutions for healthy ageing, recovery, resilience and long-term biological function.

SCIENCE AND VALIDATION

Led By Science. Backed By Evidence.

Celligenics’ platform has been developed through years of research, formulation work and biological testing across regenerative applications.

From institutional collaborations to peer-reviewed validation and internal platform data, each layer of evidence helps build confidence in the science behind Celligenics’ secretome technologies.

Institutional Validation

Research collaboration with NTU Singapore and SRIS provided third-party validation of Celligenics’ secretome technology in chronic wound healing models.

Read more
Institutional Validation

Research collaboration with NTU Singapore and SRIS provided third-party validation of Celligenics’ secretome technology in chronic wound healing models.

Read more
Peer-Reviewed Publication

Published research supports Celligenics’ secretome activity in a wound-relevant in vitro delayed scratch closure model for chronic wound evaluation.

Read more
Peer-Reviewed Publication

Published research supports Celligenics’ secretome activity in a wound-relevant in vitro delayed scratch closure model for chronic wound evaluation.

Read more
Internal Platform Data

In-vitro, preclinical and platform quality data support regenerative activity, consistency and scalability, with selected technical data available to qualified partners.

Internal Platform Data

In-vitro, preclinical and platform quality data support regenerative activity, consistency and scalability, with selected technical data available to qualified partners.

Selected technical data and publications are available upon request for qualified partners.

Selected technical data and publications are available upon request for qualified partners.

Our Story

The Celligenics Story

Established in 2016, Celligenics is an A*STAR spin-off and Singapore-based regenerative biotech company developing secretome-based technologies for real-world regenerative applications.

From its research foundation, Celligenics has grown through scientific development, strategic collaborations and commercial translation, building the capabilities to move regenerative science from research into practical use.

Celligenics has been recognised among A*STAR’s top biotech start-ups in 2018 and as a Top 15 finalist for Singapore’s Emerging Enterprise Award in 2021.

A*STAR Spin-Off Foundation

Celligenics was established in Singapore to advance regenerative biologics based on stem cell and secretome science.

A*STAR Spin-Off Foundation

Celligenics was established in Singapore to advance regenerative biologics based on stem cell and secretome science.

A*STAR Spin-Off Foundation

Celligenics was established in Singapore to advance regenerative biologics based on stem cell and secretome science.

2016
2016
2019
2020
2021
2024
2026
2016
2019
2020
2021
2024
2026
2016
2019
2020
2021
2024
2026
2016
2016
2019
2020
2021
2024
2026
2016
2019
2020
2021
2024
2026
2016
2019
2020
2021
2024
2026
2016
2016
2019
2020
2021
2024
2026
2016
2019
2020
2021
2024
2026
2016
2019
2020
2021
2024
2026
partners and collaborators

Built With Leading Institutions And Partners

Celligenics works with leading research institutions, clinical networks, and commercial partners to develop, validate, and bring secretome technology to market.

Team & Advisors

Science-led. Commercially Driven.

Celligenics combines enterprise leadership, commercial strategy and scientific expertise to translate regenerative science into real-world impact.

Executive Leadership

Board Directors

Scientific Advisory

NEWS AND UPDATES

Impact Where It Matters

Follow Celligenics’ latest progress across research, partnerships, platform development and commercial milestones.

All News
All News

May 8, 2024

Celligenics Publishes Latest Scientific Paper On Springer Nature

Celligenics is proud to announce the publication of our latest scientific breakthrough: "Development and functional testing of a novel in vitro delayed scratch closure assay" in the Springer Nature journal, Histochemistry and Cell Biology.

Read more

May 8, 2024

Celligenics Publishes Latest Scientific Paper On Springer Nature

Celligenics is proud to announce the publication of our latest scientific breakthrough: "Development and functional testing of a novel in vitro delayed scratch closure assay" in the Springer Nature journal, Histochemistry and Cell Biology.

Read more

May 8, 2024

Celligenics Publishes Latest Scientific Paper On Springer Nature

Celligenics is proud to announce the publication of our latest scientific breakthrough: "Development and functional testing of a novel in vitro delayed scratch closure assay" in the Springer Nature journal, Histochemistry and Cell Biology.

Read more

Mar 21, 2023

Celligenics Announces China Market Entry, & Signs MOU With West China Hospital

Celligenics is pleased to announce that we have signed a memorandum of understanding with West China Hospital (Hua Xi) of Sichuan University at the 22nd Singapore-Sichuan Trade and Investment Committee Meeting.

Read more

Mar 21, 2023

Celligenics Announces China Market Entry, & Signs MOU With West China Hospital

Celligenics is pleased to announce that we have signed a memorandum of understanding with West China Hospital (Hua Xi) of Sichuan University at the 22nd Singapore-Sichuan Trade and Investment Committee Meeting.

Read more

Mar 21, 2023

Celligenics Announces China Market Entry, & Signs MOU With West China Hospital

Celligenics is pleased to announce that we have signed a memorandum of understanding with West China Hospital (Hua Xi) of Sichuan University at the 22nd Singapore-Sichuan Trade and Investment Committee Meeting.

Read more

Mar 21, 2023

Celligenics, NTU, & SRIS Collaborate On New Therapy For Chronic Wounds (Sep 2021)

Celligenics is pleased to announce that we have signed a research collaboration agreement with local research institutes, Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chien School of Medicine (LKCMedicine) and the Skin Research Institute of Singapore (SRIS), under the Skin Innovation Grant (SIG).

Read more

Mar 21, 2023

Celligenics, NTU, & SRIS Collaborate On New Therapy For Chronic Wounds (Sep 2021)

Celligenics is pleased to announce that we have signed a research collaboration agreement with local research institutes, Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chien School of Medicine (LKCMedicine) and the Skin Research Institute of Singapore (SRIS), under the Skin Innovation Grant (SIG).

Read more

Mar 21, 2023

Celligenics, NTU, & SRIS Collaborate On New Therapy For Chronic Wounds (Sep 2021)

Celligenics is pleased to announce that we have signed a research collaboration agreement with local research institutes, Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chien School of Medicine (LKCMedicine) and the Skin Research Institute of Singapore (SRIS), under the Skin Innovation Grant (SIG).

Read more

GET IN TOUCH

Partner With Celligenics

We welcome partnerships to explore new opportunities together at the frontier of regenerative science, across global markets.

Or email us at info@celligenics.com

GET IN TOUCH

Partner With Celligenics

We welcome partnerships to explore new opportunities together at the frontier of regenerative science, across global markets.

Or email us at info@celligenics.com

GET IN TOUCH

Partner With Celligenics

We welcome partnerships to explore new opportunities together at the frontier of regenerative science, across global markets.

Or email us at info@celligenics.com